Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Growing evidence to support use of stem cell transplantation

Growing evidence to support use of stem cell transplantation for a select group of MS patients

Following TVNZs Sunday programme last night on people with multiple sclerosis seeking stem cell transplantation overseas for their MS, the Multiple Sclerosis Society of New Zealand (MSNZ) confirms its support for the use of this treatment within a clinical trial setting under established international protocols.

“Current research shows that Autologous Haematopoietic Stem Cell Transplant (AHSCT) is a viable treatment option for people with MS who are early in their disease course, with highly active relapsing MS and have tried and failed at least one, if not two of the treatments currently funded by PHARMAC,” commented MSNZ Vice President Neil Woodhams. “The criteria for observational studies in Europe and Australia follow these criteria and we would like to see the same opportunity here in New Zealand.”

Earlier this year MSNZ met with the Acting Chief Medical Officer of the Ministry of Health to present the growing evidence to support the use of AHSCT. MSNZ is calling on the Ministry of Health to make AHSCT available on the public health system under an approved criteria based on the evidence. MSNZ believes the number of people who would qualify for the treatment would be relatively small.

“This is a prime opportunity for a process to be developed alongside an observational study and we are investigating options to link into wider international studies if we do not have the numbers here,” says Woodhams. “The treatment still comes with risks but many people with active MS and rapidly-increasing disability will seek any option to improve their quality of life.”

As part of MSNZ’s 50th Anniversary celebrations the Society recently invited international Stem Cell Transplant expert, Dr Riccardo Saccardi, based at Careggi University Hospital in Florence, Italy, to present at two public lectures in Christchurch and Auckland.

MSNZ makes it clear that not everyone who receives AHSCT has benefited from the treatment. “While we are aware that there are some people who have not achieved successful outcomes, there is an identifiable group of people with MS who are doing extremely well following AHSCT treatment in New Zealand and globally,” says Woodhams. “Dr Saccardi clearly highlighted the need for robust research and clear information to help clinicians, patients and regulating bodies make decisions based on the proven evidence.”

“It is important that people receive the right type of stem cell treatment,” says Woodhams. “We have concerns that some people could be put at unnecessary risk searching for a cure. We support patient choice and want to see a New Zealand treatment option based on the latest research available. In all cases, people with MS should seek qualified advice from an MS specialist neurologist about the likelihood of success before moving ahead with any treatment.”

MSNZ is aware that people with MS are raising over $100,000 dollars to personally fund overseas AHSCT treatment. New Zealand has performed AHSCT treatment for many years with cancer patients. “Going abroad presents many risks for patients,” commented Woodhams. “People are being treated in countries where:
English isn’t the first language,
systems and processes can be different,
are away from home for several months, often without family support and,
on their return, require on-going support and monitoring from clinicians who haven’t been involved in their treatment and care plan.

We need to keep people safe and give them access to be best treatment options here in New Zealand where the evidence suggests they would benefit.”

Another key aspect in New Zealand is the relatively poor access to Disease Modifying Treatments (DMTs) compared with other first world countries. International studies recommend that people have tried and failed at least one, if not two, DMTs, some of which are available in NZ. “DMTs are designed to reduce or prevent relapses, yet our current system requires them to have a second relapse first before treatment is approved. Earlier access to DMTs would mean some people currently seeking HSCT would not need the treatment as there is increasing evidence of the efficacy of DMTs particularly where early access is available.” says Woodhams.
MSNZ has met with PHARMAC and made an official submission to review the entry and exit criteria for the currently available DMTs “International recommendations and research supports our request that beginning treatment earlier than currently allowed in NZ will improve long term outcomes for people with MS, preserve brain health and reduce the likelihood of irreparable damage which can be caused but further relapses.”

ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Reserve Bank: Ongoing Monetary Tightening
The Monetary Policy Committee today increased the Official Cash Rate (OCR) to 3 percent from 2.5 percent. The Committee agreed it remains appropriate to continue to tighten monetary conditions... More>>



Statistics: Weekly Earnings Rise As More In Full-time Employment

Median weekly earnings from wages and salaries rose by 8.8 percent to $1,189 in the year to the June 2022 quarter, Stats NZ said today... More>>



Bell Gully: Uncertainty Ahead With New Unconscionable Conduct Legislation

new prohibition against ‘unconscionable conduct’ in trade is one of a number of changes to the Fair Trading Act 1986 that come into force from 16 August 2022. The new prohibition may have wide-ranging implications for many businesses... More>>


Electricity Authority: Imposes Interim Restrictions On Very Large Electricity Contracts

Consumers of electricity will be protected from potentially paying more than they should due to the impact of very large electricity contracts on wholesale prices, under urgent changes announced today by the Electricity Authority... More>>


Westpac: Economic Overview, August 2022 – Pushing Through

The New Zealand economy faces some lean growth in the year ahead as households’ budgets are squeezed, according to Westpac’s latest Economic Overview... More>>


Kiwi Group Holdings: Fisher Funds Acquires Kiwi Wealth Business

Kiwi Group Holdings Limited (KGHL) today announced the sale of Kiwi Wealth to Fisher Funds for NZ$310 million... More>>